Shares of Thermo Fisher Scientific (TMO) - Get Report were higher during mid-morning trading on Friday following after Cantor Fitzgerald initiated coverage of the stock with an overweight rating and a $194 price target.

Management at the Waltham, MA-based biotechnology product development firm is "well positioned" to take advantage of positive secular trends and "attractive" end markets, Cantor analyst Bryan Brokmeier noted.

Thermo Fisher's strong reputation with consumers in a "highly-fragmented" industry will create organic growth opportunities at the "likely" expense of weaker competition, Brokmeier added.

Jim Cramer and Real Money columnists discuss the latest from President Donald Trump and the GOP efforts to repeal and replace the Affordable Care Act. See which stocks they are discussing and get his insights or analysis with a free trial subscription to Real Money.